Schedule One - Aptamer Group Plc

RNS Number : 8854U

AIM

08 December 2021

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

Aptamer Group plc

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES):

Second Floor

Bio Centre

Innovation Way

Heslington

York

YO10 5NY

COUNTRY OF INCORPORATION:

England and Wales

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

www.aptamergroup.com

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

Aptamer Group operates within the life sciences sector and is a leader in the provision of aptamer discovery and selection services and in developing aptamer-based reagents. The Company operates across three life science sectors: custom services (research and bioprocessing tools), diagnostics and therapeutics. The Company strives to deliver transformational solutions that meet the needs of developers and users of diagnostic platforms, scientific researchers and companies involved in drug development and manufacturing.

Aptamers are synthetic nucleic acid-based biological molecules, selected based on their specific characteristics to bind to a 'target' of interest. Targets can include proteins, cells, viruses or small molecules (e.g. therapeutic drug molecules). The ability to bind in a predictable, measurable and controllable way to such targets, creates opportunities in diagnostics, therapeutics, bioprocessing and research applications. The target binding characteristics of aptamers means that they are often thought of as 'chemical antibodies' and positions them as a disruptive technology in the well-established global antibody market worth over $145.7bn per annum (2021) and expected to reach $248.9bn by 2026.

Aptamer Group has developed a proprietary platform for the high-throughput, automated development of aptamer binders with tuneable properties to fulfil clients' and partners' needs. The Group's business model is to provide contract research services on a fee-for-service basis plus longer term upside potential from ongoing royalty and licensing revenues where the Group's reagents are taken forward by customers into commercial applications.

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

[TBC] Ordinary Shares of 0.1p each

Issue price of [TBC] p

No restrictions on transfer

No shares are to be held in treasury

CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Capital to be raised on Admission: £TBC million

Anticipated market capitalisation on Admission: £TBC million

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

[TBC] per cent.

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

None

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Directors:

Dr Arron Craig Tolley - Chief Executive Officer

Dr David Harry John Bunka - Chief Technical Officer

Eleanor Margaret Courtman-Stock - Chief Financial Officer

Dr John David Richards - Non-Executive Director

Proposed Directors:

Dr Ian David Gilham - Non-Executive Chairman

Angela Hildreth - Non-Executive Director

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Shareholder	Percentage - pre- Admission	Percentage - post-Admission
Dr Arron Craig Tolley	26.44	TBC
Dr David Harry John Bunka	20.96	TBC
Meneldor AG Cooperatie I U.A.	17.38	TBC
Stephen Hull	5.11	TBC

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

Turner Pope Investments (TPI) Ltd

Deloitte LLP

Stephenson Harwood LLP

(i) ANTICIPATED ACCOUNTING REFERENCE DATE

(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

(i) The current accounting reference date of the Company is 30 June

(ii) 30 June 2021

(iii) Accounts for 6 months period ending 31 December 2021 (to be notified by 31 March 2022); Accounts for year ending 30 June 2022 (by 31 December 2022); Accounts for 6 months period ending 31 December 2022 (by 31 March 2023)

EXPECTED ADMISSION DATE:

Mid-December 2021

NAME AND ADDRESS OF NOMINATED ADVISER:

SPARK Advisory Partners Limited

5 St John's Lane

Farringdon

London

EC1M 4BH

NAME AND ADDRESS OF BROKER:

Liberum Capital Limited

Ropemaker Place

25 Ropemaker Street

London EC2Y 9LY

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

The Admission Document, which contains full details about the Company and the admission of its securities to trading on AIM, will be available for download from the Company's website: www.aptamergroup.com

THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY

The QCA Corporate Governance Code

DATE OF NOTIFICATION:

8 December 2021

NEW/ UPDATE:

NEW

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

PAAQDLFBFLLEFBD

Date	8 Dec 2021
Time	08:00:03
Category	Capital structure
ID	8854U

Date	8 Dec 2021
Time	08:00:03
Category	Capital structure
ID	8854U

t

RNS Metadata

RNS Metadata

Schedule One - Aptamer Group Plc